據報國壽資產ABS項目獲批
據《上海證券報》報道,中國人壽資產管理有限公司向上海證券交易所和深圳證券交易所申報的中國人壽「創工融資租賃資產支持專項計劃」和中國人壽「創科供應鏈資產支持專項計劃」,於日前獲得兩家交易所出具的無異議函,實現保險資管公司資產證券化業務試點的新突破。
據悉,國壽創工項目由江蘇徐工工程機械租賃有限公司作為原始權益人,基礎資產為徐工集團各大主機廠製造的工程機械設備,融入徐工集團的高端產業技術以及科技專利,為國壽資產重點加強新質生產力領域金融供給、有效提升科技金融質效和持續升級先進製造業金融服務的重要舉措。
國壽創科項目由萬科集團作為核心企業,以上下游供應商、施工方對債務人的應收賬款作為基礎資產,切實有效緩解中小企業面臨的融資難、融資貴問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.